HEAL Initiative: Therapeutics Development for Opioid Use Disorder in Patients with Co-occurring Mental Disorders (UG3/UH3 - Clinical Trial Optional)

THE PURPOSE OF THIS FOA IS TO SUPPORT RESEARCH THAT ACCELERATES THE DISCOVERY AND DEVELOPMENT OF SAFE AND EFFECTIVE THERAPEUTICS FOR OUD IN PATIENTS WITH CO-OCCURRING COMD. THE THERAPEUTIC INTERVENTIONS MAY INCLUDE MEDICATIONS, DEVICES, OR DIGITAL THERAPEUTICS. THE GOAL IS TO SUPPORT RESEARCH THAT ADDRESSES THE URGENT NEED TO HAVE SAFE AND EFFECTIVE THERAPEUTICS FOR OUD IN PATIENTS WITH CO-OCCURRING COMD.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See full announcement for additional details on eligibility.